Association Between Gene Polymorphism of IL17 and IL 23 in Patients With COVID 19

Sohag University1 site in 1 country120 target enrollmentJune 3, 2021

ConditionsCOVID-19 Respiratory Infection

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: COVID-19 Respiratory Infection
Sponsor: Sohag University
Enrollment: 120
Locations: 1
Primary Endpoint: genotyping of IL 23
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

rates are in such considerable amount among large population base. The pathogenesis of COVID-19 implicates a potent inflammatory response, involving a complex group of mediators including interleukins. These pleiotropic cytokines are secreted at the region of inflammation and released into the circulation by a variety of different cell types, including macrophages, lymphocytes, endothelial cells, epithelial cells during sepsis and acute organ injuries. There has recently found a number of studies reporting that the cytokine storms take part in the course of COVID-19

Detailed Description

Aim Of The Study 1. To evaluate if there is an association between the IL-17, IL-23 gene polymorphism in Patients With COVID 19 by real-time PCR 2. To measure the serum level of IL17 by ELISA in COVID 19 patients by ELISA. 3. To detect if there is an association between gene polymorphism of IL17 and IL23 and severity of a condition in patients with COVID 19 Study design: a cross-sectional study. The blood samples will be collected from patient records in COVID19 isolation hospitals in sohag governorate and isolation department in sohag university hospitals.

Registry

clinicaltrials.gov

Start Date

June 3, 2021

End Date

December 3, 2021

Last Updated

3 years ago

Study Type

Observational

Sex

All